Clinical Trial Update: Efficiency, Safety and Portability of Neovasculgen [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update reporting the completion of Phase 2 and Phase 3 studies evaluating the efficiency, safety, and portability of Neovasculgen for Peripheral …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral Arterial Disease

Drugs mentioned

• Neovasculgen (VEGF165 plasmid DNA (pl-VEGF165))

Snippet

Sponsor: Artgen Biotech | Conditions: Peripheral Arterial Disease | Phase 2, Phase 3 | Status: COMPLETED